Kopran Limited (KOPRAN) shares Q2 2026-27 financial results, highlighting revenue growth and operational performance.
Kopran Limited (KOPRAN) announces successful EU Medicine Authority GMP inspection at Khopoli facility, with no critical observations.
Kopran Limited (NSE: KOPRAN) Q1 FY 2026-27 results: financial highlights, operational performance, and strategic outlook.
Kopran Limited (KOPRAN) unveils its FY 2025-26 corporate presentation, highlighting significant financial and operational milestones.